JP2014503499A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014503499A5 JP2014503499A5 JP2013540060A JP2013540060A JP2014503499A5 JP 2014503499 A5 JP2014503499 A5 JP 2014503499A5 JP 2013540060 A JP2013540060 A JP 2013540060A JP 2013540060 A JP2013540060 A JP 2013540060A JP 2014503499 A5 JP2014503499 A5 JP 2014503499A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- ldh
- ldh5
- ldh4
- tumor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (21)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41513910P | 2010-11-18 | 2010-11-18 | |
| US41515510P | 2010-11-18 | 2010-11-18 | |
| US41515810P | 2010-11-18 | 2010-11-18 | |
| US41512210P | 2010-11-18 | 2010-11-18 | |
| US41515610P | 2010-11-18 | 2010-11-18 | |
| US41513610P | 2010-11-18 | 2010-11-18 | |
| US41514710P | 2010-11-18 | 2010-11-18 | |
| US61/415,136 | 2010-11-18 | ||
| US61/415,139 | 2010-11-18 | ||
| US61/415,155 | 2010-11-18 | ||
| US61/415,158 | 2010-11-18 | ||
| US61/415,147 | 2010-11-18 | ||
| US61/415,156 | 2010-11-18 | ||
| US61/415,122 | 2010-11-18 | ||
| US201161510648P | 2011-07-22 | 2011-07-22 | |
| US201161510653P | 2011-07-22 | 2011-07-22 | |
| US201161510660P | 2011-07-22 | 2011-07-22 | |
| US61/510,653 | 2011-07-22 | ||
| US61/510,648 | 2011-07-22 | ||
| US61/510,660 | 2011-07-22 | ||
| PCT/US2011/061440 WO2012068483A1 (en) | 2010-11-18 | 2011-11-18 | Preselection of subjects for therapeutic treatment based on hypoxic status |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014503499A JP2014503499A (ja) | 2014-02-13 |
| JP2014503499A5 true JP2014503499A5 (enExample) | 2015-01-15 |
Family
ID=45217699
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013540060A Pending JP2014503499A (ja) | 2010-11-18 | 2011-11-18 | 低酸素状態に基づく治療に適した被験体の事前選択 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US20120128665A1 (enExample) |
| EP (1) | EP2640385A1 (enExample) |
| JP (1) | JP2014503499A (enExample) |
| CN (1) | CN103327976A (enExample) |
| AU (1) | AU2011329681A1 (enExample) |
| CA (1) | CA2817564A1 (enExample) |
| WO (1) | WO2012068483A1 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5441691B2 (ja) | 2006-05-25 | 2014-03-12 | シンタ ファーマシューティカルズ コーポレーション | Ｈｓｐ９０活性を調節するトリアゾール化合物 |
| EP2323737A2 (en) | 2008-08-08 | 2011-05-25 | Synta Pharmaceuticals Corp. | Triazole compounds that modulate hsp90 activity |
| US9205086B2 (en) | 2010-04-19 | 2015-12-08 | Synta Pharmaceuticals Corp. | Cancer therapy using a combination of a Hsp90 inhibitory compounds and a EGFR inhibitor |
| AU2012332424A1 (en) | 2011-11-02 | 2014-06-05 | Synta Pharmaceuticals Corp. | Combination therapy of Hsp90 inhibitors with platinum-containing agents |
| WO2013067162A1 (en) | 2011-11-02 | 2013-05-10 | Synta Pharmaceuticals Corp. | Cancer therapy using a combination of hsp90 inhibitors with topoisomerase i inhibitors |
| WO2013074594A1 (en) | 2011-11-14 | 2013-05-23 | Synta Pharmaceuticals Corp. | Combination therapy of hsp90 inhibitors with braf inhibitors |
| WO2013170182A1 (en) * | 2012-05-11 | 2013-11-14 | Synta Pharmaceuticals Corp. | Treating cancer with an hsp90 inhibitory compound |
| AU2013262914A1 (en) * | 2012-05-16 | 2014-11-06 | Synta Pharmaceuticals Corp. | Pre-selection of subjects for therapeutic treatment with an Hsp90 inhibitor based on hypoxic status |
| US20160022757A1 (en) * | 2013-03-15 | 2016-01-28 | Icahn School Of Medicine At Mount Sinai | Therapeutic methods for treating solid tumors and related diagnostic methods |
| WO2015089443A2 (en) * | 2013-12-12 | 2015-06-18 | The Brigham And Women's Hospital, Inc. | Treating neurodegenerative disease |
| SMT202100674T1 (it) | 2014-08-11 | 2022-01-10 | Acerta Pharma Bv | Combinazioni terapeutiche di un inibitore di btk e un inibitore di bcl-2 |
| WO2016024232A1 (en) | 2014-08-11 | 2016-02-18 | Acerta Pharma B.V. | Therapeutic combinations of a btk inhibitor, a pi3k inhibitor, a jak-2 inhibitor and/or a cdk 4/6 inhibitor |
| RS63364B1 (sr) | 2014-08-11 | 2022-07-29 | Acerta Pharma Bv | Terapeutske kombinacije btk inhibitora, pd-1 inhibitora i/ili pd-l1 inhibitora |
| CN104267191B (zh) * | 2014-09-09 | 2016-03-23 | 北京大学口腔医学院 | 口腔鳞状细胞癌的生物标志物及其应用 |
| WO2016073669A1 (en) * | 2014-11-05 | 2016-05-12 | Vojo Vukovic | Combination therapy of hsp90 inhibitory compounds with mtor inhibitors |
| WO2017136326A1 (en) * | 2016-02-01 | 2017-08-10 | Board Of Regents, The University Of Texas System | Using spectral ct to diagnose thyroid nodules |
| CN105709239A (zh) * | 2016-03-22 | 2016-06-29 | 山东省肿瘤医院 | 一种非小细胞肺癌放疗相关的HIF-1α的抑制剂 |
| US20240295567A1 (en) * | 2021-06-29 | 2024-09-05 | Kyoto University | Hypoxia biomarker and use thereof |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4250255A (en) | 1977-07-11 | 1981-02-10 | Eastman Kodak Company | Assay method for isoenzyme activity |
| US6242208B1 (en) | 1988-07-15 | 2001-06-05 | International Reagents Corporation | LDH1 assay |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| US5362718A (en) | 1994-04-18 | 1994-11-08 | American Home Products Corporation | Rapamycin hydroxyesters |
| US5747498A (en) | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
| CO4950519A1 (es) | 1997-02-13 | 2000-09-01 | Novartis Ag | Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion |
| UA74803C2 (uk) | 1999-11-11 | 2006-02-15 | Осі Фармасьютікалз, Інк. | Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування |
| US7087613B2 (en) | 1999-11-11 | 2006-08-08 | Osi Pharmaceuticals, Inc. | Treating abnormal cell growth with a stable polymorph of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride |
| EP1620109A2 (en) | 2003-04-25 | 2006-02-01 | Gilead Sciences, Inc. | Kinase inhibitor phosphonate conjugates |
| ES2594874T3 (es) | 2004-11-18 | 2016-12-23 | Synta Pharmaceuticals Corp. | Compuestos de triazol que modulan la actividad de HSP90 |
| GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
| CA2648291A1 (en) * | 2006-04-04 | 2007-11-01 | Stc.Unm | Swellable particles for drug delivery |
| GB0610925D0 (en) * | 2006-06-02 | 2006-07-12 | Novartis Ag | Use of vascular endothelial growth factor receptor inhibitors for the treatment of cancer |
| SE530596C2 (sv) | 2006-10-13 | 2008-07-15 | Mathias Karlsson | Metod att fastställa syrebrist i blod från skalpen under förlossning |
| CA2670134A1 (en) | 2006-11-21 | 2008-08-28 | Beth Israel Deaconess Medical Center | Hypoxia related genes and proteins for the treatment and diagnosis of pregnancy related complications |
| US20080318241A1 (en) * | 2007-06-18 | 2008-12-25 | The Regents Of The University Of Michigan | Methods and Systems for Detecting Antiangiogenesis |
-
2011
- 2011-11-18 US US13/300,221 patent/US20120128665A1/en not_active Abandoned
- 2011-11-18 EP EP11793607.0A patent/EP2640385A1/en not_active Withdrawn
- 2011-11-18 AU AU2011329681A patent/AU2011329681A1/en not_active Abandoned
- 2011-11-18 CA CA2817564A patent/CA2817564A1/en not_active Abandoned
- 2011-11-18 JP JP2013540060A patent/JP2014503499A/ja active Pending
- 2011-11-18 WO PCT/US2011/061440 patent/WO2012068483A1/en not_active Ceased
- 2011-11-18 CN CN2011800653411A patent/CN103327976A/zh active Pending
-
2013
- 2013-12-17 US US14/109,543 patent/US20140178366A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014503500A5 (enExample) | ||
| JP2013545759A5 (enExample) | ||
| JP7793556B2 (ja) | 抗体－薬物コンジュゲートとａｔｒ阻害剤との組み合わせ | |
| KR102237803B1 (ko) | 항 trop2 항체-약물 컨쥬게이트 | |
| AU2017205101B2 (en) | Inhibitors of ataxia-telangiectasia mutated and Rad3-related protein kinase (ATR) for use in methods of treating cancer | |
| JP6066421B2 (ja) | 癌の治療のための低酸素活性化プロドラッグおよび血管新生阻害剤の投与方法 | |
| KR20240130087A (ko) | 항체-약물 접합체와 atr 저해제의 조합 | |
| JPWO2020130125A1 (ja) | 抗体−薬物コンジュゲートとキナーゼ阻害剤の組み合わせ | |
| Speranza et al. | BKM-120 (Buparlisib): a phosphatidyl-inositol-3 kinase inhibitor with anti-invasive properties in glioblastoma | |
| AU2015317327B9 (en) | Pyridinyl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors | |
| Guo et al. | Biomimetic nanoparticles for siRNA delivery in the treatment of leukaemia | |
| US20230372527A1 (en) | Combination of antibody-drug conjugate and parp1 selective inhibitor | |
| JP2013543011A (ja) | 癌の治療法 | |
| WO2015104292A2 (en) | Compounds for use in treating or preventing cancerous diseases | |
| RU2015105786A (ru) | Комбинированная терапия ингибиторами igf1r и pi3k | |
| JP2018503697A5 (enExample) | ||
| JP2014513097A5 (enExample) | ||
| Xia et al. | Dihydroartemisinin induces cell apoptosis through repression of UHRF1 in prostate cancer cells | |
| US9844552B2 (en) | Methods of treating fibrosis | |
| US20240398767A1 (en) | Inhibitors of the mtdh-snd1 protein complex for cancer therapy | |
| JP2018528949A5 (enExample) | ||
| TW202423446A (zh) | 用於治療實性瘤之包含 krasg12c 抑制劑及 egfr 抑制劑之組成物及方法 | |
| Couderc et al. | Targeting the PI3K/mTOR pathway in murine endocrine cell lines: in vitro and in vivo effects on tumor cell growth | |
| Ye et al. | Olaparib reverses prostate cancer resistance to Rapamycin by promoting macrophage polarization towards the M1 phenotype | |
| Li et al. | XHL11, a novel selective EGFR inhibitor, overcomes EGFRT790M-mediated resistance in non-small cell lung cancer |